Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
•
Non-Tubercular Mycobacteria
Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?
Answer from: at Academic Institution
No, not at this time. Intriguing, but not sure we know enough yet.
Sign in or Register to read more
Answer from: at Academic Institution
I ordered it once but it didn’t help in the diagnosis. The patient expired from multiple organ dysfunction syndrome (MODS) and sepsis. It is an expensive test, so I won’t be ordering it routinely.
Sign in or Register to read more
16531
16652
Related Questions
Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
Have you incorporated the use of steroids for patients with severe community-acquired pneumonia?
What further evaluation do you pursue for patients who present with vague symptoms such as subjective fevers or intermittent night sweats, who have no pulmonary symptoms but have a positive IGRA?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?